Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Impact · against what's priced in

Tarsus Pharmaceuticals demonstrates strong commercial execution with Q1 XDEMVY sales exceeding $145 million and a reaffirmation of its $670-700 million full-year guidance. The initiation of the Phase 2 Calliope trial for Lyme disease prevention adds a long-term optionality catalyst to the company's valuation.

TARS+0.70: No priced-in read yet

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

What matters in this story

My 'Eye' Is On Tarsus Pharmaceuticals

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

What matters in this story

My 'Eye' Is On Tarsus Pharmaceuticals

How each ticker is affected

Track these names every morning.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

Hyatt: 3 Key Takeaways for Long-Term Investors

Coca-Cola vs. UPS: Which Dividend Stock Could Make You Richer Over the Next 10 Years?

Gaming and Leisure Properties: 3 Key Takeaways for Long-Term Investors

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

What matters in this story

Next reads from the same story arc

My 'Eye' Is On Tarsus Pharmaceuticals

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

What matters in this story

Next reads from the same story arc

My 'Eye' Is On Tarsus Pharmaceuticals

How each ticker is affected

Track these names every morning.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

Hyatt: 3 Key Takeaways for Long-Term Investors

Coca-Cola vs. UPS: Which Dividend Stock Could Make You Richer Over the Next 10 Years?

Gaming and Leisure Properties: 3 Key Takeaways for Long-Term Investors